NCT06880250Enrolling by invitation
Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease
Open-label Comparative Cohort Non-interventional Epidemiological Study of the Efficacy and Safety of Enzyme Replacement Therapy in Russian Patients With Fabry Disease
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The goal of this observational study is to learn how enzyme replacement therapy works in patients with Fabry disease. The main question it aims to answer is: What medical problems do participants have? Participants already on enzyme replacement therapy as part of their regular medical care for Fabry disease will be observed as usual. Their data will be collected by their doctor.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 11 Mar 2025
- Start date
- 24 Mar 2025
- Primary completion date
- Jan 2027
- Lead sponsor
- NPO Petrovax
- Diseases
- Fabry disease
- NCT number
- NCT06880250
What you commit to
- Study type: Observational
- Planned participants: 100
- From 24 Mar 2025 to the primary completion date, Jan 2027
- 23 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Renal replacement therapy or kidney transplantation;
Other illness
- Critical illness unrelated to Fabry disease;
Other
- Pregnancy or breastfeeding;
- Refusal of the patient (or patient's legal representative) from further participation in the study or medical care.
Who the study is looking for
- Men and women with a confirmed diagnosis of Fabry disease;
- Prescribed course of enzyme replacement therapy with any drug (Fabagal, Fabrazyme, Replagal);
- Age 8 - 65 years;
- Signed informed consent of the patient and/or patient's legal representative for participation in the study and processing of personal data.
Age in the registry: 8 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (23)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.